TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03862157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03872284

Intervention type: OTHER
Intervention: oculomotor movement recordings, neurovisual assessment
Description: Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
Study: NCT04371081

Intervention type: DEVICE
Intervention: Amplatzer Piccolo Occluder
Description: Interventional placement of vascular occluder
Study: NCT03391960

Intervention type: DEVICE
Group type: OTHER
Intervention: Passive disinfection device
Description: Add use of passive disinfection cap to existing central line needleless connector infection control procedure
Study: NCT04490057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Description: Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Description: Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Description: Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Description: Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Description: Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Description: Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline or bupropion
Description: Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline or bupropion
Description: Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will be financially rewarded for abstinence to tobacco.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will be financially rewarded for abstinence to tobacco.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will be financially rewarded for abstinence to tobacco.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will be financially rewarded for abstinence to tobacco.
Study: NCT06766396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postpartum Intrauterine Contraceptive Device (PPIUCD).
Description: Participants in the intervention arm will receive a postpartum intrauterine contraceptive device (PPIUCD) immediately after delivery. For vaginal deliveries, the PPIUCD will be inserted manually using Kelly's forceps under aseptic conditions, while for cesarean deliveries, the device will be inserted before uterine incision closure. All insertions will be performed by trained healthcare professionals
Study: NCT06764212

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: M-mode ultrasonography images of the fascia under the trapezius muscle will be recorded during 3 different movements.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: M-mode ultrasonography images of the fascia under the trapezius muscle will be recorded during 3 different movements.
Study: NCT06766084

Intervention type: PROCEDURE
Intervention: CABG
Description: All patients underwent isolated CABG and retrospectively followed to asses clinical outcomes of the two different revascularization techniques

Intervention type: PROCEDURE
Intervention: CABG
Description: All patients underwent isolated CABG and retrospectively followed to asses clinical outcomes of the two different revascularization techniques
Study: NCT03545295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 2
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 3
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 3
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 3
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
Study: NCT02222233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA delayed release (enteric coated) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA particulate
Study: NCT06767982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin (BCG)
Description: In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin (BCG)
Description: In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients
Study: NCT06768619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single-dose of test formulation+single-dose of reference formulation
Description: Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: single-dose of reference formulation+single-dose of test formulation
Description: Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
Study: NCT01648725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A short preanesthetic hypnosis before induction of anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Standard care before induction of anesthesia
Study: NCT02165189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram (\[kg\]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
Study: NCT01311375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: w3 supplement in SCI
Description: supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo+ capsule CA-D
Study: NCT02162719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
Study: NCT04180137

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins
Description: Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins
Description: Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
Study: NCT01666743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
Study: NCT01719913

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High gluten
Description: Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low gluten
Description: Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
Study: NCT03843541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg
Description: NAC will be administered twice a day, morning and evening, during treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride 30 mg
Description: Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered twice a day, morning and evening, during treatment period.
Study: NCT02346747

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vigil
Description: The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media \[10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)\]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection.
Study: NCT06768346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia will be delivered in combination with each instillation using the Combat BRS system
Description: The Combat BRS system is a temperature controlled fluid recirculation system for the delivery of hyperthermic intravesical chemotherapy. The chemotherapy fluid is circulated in a closed system and warmed by an external isolated dry system using a novel innovative laminated aluminium foil heat exchanger with a small priming volume.
Study: NCT02067455

Intervention type: OTHER
Group type: OTHER
Intervention: adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography
Study: NCT02946450

Intervention type: DRUG
Intervention: Other: Not applicable-observational study
Study: NCT03401840

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative hypofractionated stereotactic radiotherapy
Description: total dose of 36Gy in 6 fractions over 11-13 days
Study: NCT04497844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive Niraparib 200 mg once daily.
Study: NCT00991029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Loading dose of 8 tablets followed by one tablet daily for 89 days
Study: NCT02359578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
Study: NCT02766010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TensorTip
Description: Non Invasive screening of various physiological and hematological parameters.
Study: NCT01694069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: 400 mg/kg/day as either intermittent or continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam combination product
Description: 400 mg/kg/day as either intermittent or continuous infusion
Study: NCT01514838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral, used only during placebo run-in period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral, used only during placebo run-in period
Study: NCT03557931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4345
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4345
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: oral or depot administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: quetiapine
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Oral or depot administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olanzapine
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Oral or depot administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ziprasidone
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Oral or depot administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aripiprazole
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brexpiprazole
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brexpiprazole
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: brexpiprazole
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: Oral or depot administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paliperidone
Description: Oral or depot administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lurasidone
Description: Oral administration
Study: NCT03961061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenner mFIT (standard care)
Description: Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brenner mFIT (standard care plus mobile health components)
Description: Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~1. a mobile-enabled website,~2. diet and physical activity tracking apps and physical activity tracker~3. tailored self-monitoring feedback~4. caregiver podcasts~5. animated videos for adolescent patients~6. social support via social media.
Study: NCT00971464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eccentric viewing (EV) training
Description: Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed circuit television (CCTV)
Description: A CCTV is an electro-optical device mainly used for reading.
Study: NCT04497844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate (AA)
Description: Participants will receive AA 1000 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA)
Description: Participants will receive AA 1000 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive prednisone 5 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 5 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Niraparib
Description: Participants will receive matching placebo for Niraparib once daily.